Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

Abstract

A complex biologic network regulates kidney perfusion under physiologic conditions. This system is profoundly perturbed following renal ischemia, a leading cause of acute kidney injury (AKI) - a life-threatening condition that frequently complicates the care of hospitalized patients. Therapeutic approaches to prevent and treat AKI are extremely limited. Better understanding of the molecular pathways promoting postischemic reflow could provide new candidate targets for AKI therapeutics. Due to its role in adapting tissues to hypoxia, we hypothesized that extracellular adenosine has a regulatory function in the postischemic control of renal perfusion. Consistent with the notion that equilibrative nucleoside transporters (ENTs) terminate adenosine signaling, we observed that pharmacologic ENT inhibition in mice elevated renal adenosine levels and dampened AKI. Deletion of the ENTs resulted in selective protection in Ent1-/- mice. Comprehensive examination of adenosine receptor-knockout mice exposed to AKI demonstrated that renal protection by ENT inhibitors involves the A2B adenosine receptor. Indeed, crosstalk between renal Ent1 and Adora2b expressed on vascular endothelia effectively prevented a postischemic no-reflow phenomenon. These studies identify ENT1 and adenosine receptors as key to the process of reestablishing renal perfusion following ischemic AKI. If translatable from mice to humans, these data have important therapeutic implications.

• Authors: Almut Grenz, Jessica D Bauerle, Julee H Dalton, Douglas Ridyard, Alexander Badulak, Eunyoung Tak, Eóin N McNamee, Eric Clambey, Radu Moldovan, German Reyes, Jost Klawitter, Kelly Ambler, Kristann Magee, Uwe Christians, Kelley S Brodsky, Katya Ravid, Doo-Sup Choi, Jiaming Wen, Dmitriy Lukashev, Michael R Blackburn, Hartmut Osswald, Imogen R Coe, Bernd Nürnberg, Volker H Haase, Yang Xia, Michail Sitkovsky, Holger K Eltzschig
• Journal: The Journal of clinical investigation (J Clin Invest) Vol. 122 Issue 2 Pg. 693-710 (02 2012) ISSN: 1558-8238 [Electronic] United States
• PMID: 22269324 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Retracted Publication)

Chemical References

• Equilibrative Nucleoside Transporter 1
• Nucleoside Transport Proteins
• Phosphodiesterase Inhibitors
• Receptors, Purinergic P1
• adenosine transporter
• Dipyridamole
• Adenosine

Topics

• Acute Kidney Injury (drug therapy, metabolism, pathology)
• Adenosine (metabolism)
• Animals
• Cell Line
• Chimerism
• Dipyridamole (therapeutic use)
• Equilibrative Nucleoside Transporter 1 (antagonists & inhibitors, genetics, metabolism)
• Humans
• Ischemia (metabolism)
• Kidney (metabolism, pathology)
• Mice
• Mice, Inbred C57BL
• Mice, Knockout
• No-Reflow Phenomenon
• Nucleoside Transport Proteins (antagonists & inhibitors, metabolism)
• Phosphodiesterase Inhibitors (therapeutic use)
• Receptors, Purinergic P1 (genetics, metabolism)
• Regional Blood Flow (physiology)